Cary Street Partners’s Biogen BIIB Stock Holding History

Cary Street Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$290K	Sell	1,340 -3	-0.2%	-$574	0.01%	814
2026 Q1	$246K	Sell	1,343 -12	-0.9%	-$2.21K	0.01%	777
2025 Q4	$238K	Hold	1,355	–	–	0.01%	791
2025 Q3	$190K	Buy	+1,355	New	+$183K	﹤0.01%	800
2025 Q1	–	Sell	-1,742	Closed	-$266K	–	863
2024 Q4	$266K	Buy	+1,742	New	+$294K	0.01%	649

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cary Street Partners's BIIB Position: Q2 2026 in Review

Cary Street Partners reduced its Biogen (BIIB) stake by 0.22% in Q2 2026, selling an estimated $574 and leaving 1,340 shares worth $290K. The position accounts for 0.01% of the portfolio, ranked #814.

Cary Street Partners first reported a position in BIIB in Q4 2024 and has held it in 5 quarters since. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Cary Street Partners held 1,340 shares of Biogen worth $290K as of Q2 2026.
Cary Street Partners sold 3 Biogen shares in Q2 2026, an estimated $574.
Biogen made up 0.01% of Cary Street Partners's portfolio in Q2 2026, its #814 holding.
Cary Street Partners first reported a position in Biogen in Q4 2024 and has held it in 5 quarters since.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.